198 related articles for article (PubMed ID: 19690032)
1. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma.
Lee I; Byun BH; Lim I; Kim BI; Kong CB; Song WS; Cho WH; Koh JS; Lim SM
Medicine (Baltimore); 2018 Sep; 97(37):e12318. PubMed ID: 30212975
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
Hamada K; Tomita Y; Inoue A; Fujimoto T; Hashimoto N; Myoui A; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2009 Jan; 23(1):89-95. PubMed ID: 19205843
[TBL] [Abstract][Full Text] [Related]
4. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
Cheon GJ; Kim MS; Lee JA; Lee SY; Cho WH; Song WS; Koh JS; Yoo JY; Oh DH; Shin DS; Jeon DG
J Nucl Med; 2009 Sep; 50(9):1435-40. PubMed ID: 19690035
[TBL] [Abstract][Full Text] [Related]
5. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
[TBL] [Abstract][Full Text] [Related]
6. Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor.
Qin Z; Tang Y; Wang H; Cai W; Fu H; Li J; Ma C
J Pediatr Hematol Oncol; 2015 Jul; 37(5):396-401. PubMed ID: 25749587
[TBL] [Abstract][Full Text] [Related]
7. ¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.
Kong CB; Byun BH; Lim I; Choi CW; Lim SM; Song WS; Cho WH; Jeon DG; Koh JS; Yoo JY; Lee SY
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):728-36. PubMed ID: 23361860
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.
Gaston LL; Di Bella C; Slavin J; Hicks RJ; Choong PF
Skeletal Radiol; 2011 Aug; 40(8):1007-15. PubMed ID: 21298431
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.
Schulte M; Brecht-Krauss D; Werner M; Hartwig E; Sarkar MR; Keppler P; Kotzerke J; Guhlmann A; Delling G; Reske SN
J Nucl Med; 1999 Oct; 40(10):1637-43. PubMed ID: 10520703
[TBL] [Abstract][Full Text] [Related]
10. Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential ¹⁸F-FDG PET/CT and MRI.
Byun BH; Kong CB; Lim I; Kim BI; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1553-62. PubMed ID: 24652233
[TBL] [Abstract][Full Text] [Related]
11. Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis.
Bajpai J; Kumar R; Sreenivas V; Sharma MC; Khan SA; Rastogi S; Malhotra A; Gamnagatti S; Kumar R; Safaya R; Bakhshi S
J Pediatr Hematol Oncol; 2011 Oct; 33(7):e271-8. PubMed ID: 22193290
[TBL] [Abstract][Full Text] [Related]
12. [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
Hawkins DS; Conrad EU; Butrynski JE; Schuetze SM; Eary JF
Cancer; 2009 Aug; 115(15):3519-25. PubMed ID: 19517457
[TBL] [Abstract][Full Text] [Related]
13. Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET.
Ye Z; Zhu J; Tian M; Zhang H; Zhan H; Zhao C; Yang D; Li W; Lin N
Ann Nucl Med; 2008 Jul; 22(6):475-80. PubMed ID: 18670853
[TBL] [Abstract][Full Text] [Related]
14. Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.
Byun BH; Kim SH; Lim SM; Lim I; Kong CB; Song WS; Cho WH; Jeon DG; Lee SY; Koh JS; Chung SK
Eur Radiol; 2015 Jul; 25(7):2015-24. PubMed ID: 25680716
[TBL] [Abstract][Full Text] [Related]
15. Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma.
Huang TL; Liu RS; Chen TH; Chen WY; Hsu HC; Hsu YC
J Chin Med Assoc; 2006 Aug; 69(8):372-6. PubMed ID: 16970273
[TBL] [Abstract][Full Text] [Related]
16. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
[TBL] [Abstract][Full Text] [Related]
17. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
[TBL] [Abstract][Full Text] [Related]
18. Can pretreatment
Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
[TBL] [Abstract][Full Text] [Related]
19. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.
Im HJ; Kim TS; Park SY; Min HS; Kim JH; Kang HG; Park SE; Kwon MM; Yoon JH; Park HJ; Kim SK; Park BK
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):39-49. PubMed ID: 21953008
[TBL] [Abstract][Full Text] [Related]
20. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
Iagaru A; Masamed R; Chawla SP; Menendez LR; Fedenko A; Conti PS
Clin Nucl Med; 2008 Jan; 33(1):8-13. PubMed ID: 18097248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]